Dr Julia Deakin

Interests

I plan to experiment with brain imaging techniques and immunomics to look for early changes in psychosis. In particular, I am interested in supporting a recently identified group of patients with psychosis who have autoantibodies to the NMDA receptor or the VGKC receptor. I aim to understand the pathophysiology in order to further develop rational approaches to treatment. NARSAD has kindly provided funds for imaging in early psychosis.

Before qualifying in medicine, my research focused on the effects of pharmacological manipulations on impulsive decision making.

Research Focus

Keywords

Psychosis

Antibodies

NMDA

Clinical conditions

Bipolar disorder

NMDA receptor antibody encephalopathy

Schizophrenia

VGKC complex antibody associated encephalopathy

Equipment

Cross-sectional and cohort studies

Neuropsychological testing

Collaborators

Cambridge

Ed Bullmore

Aladair Coles

Peter Jones

Paul Lyons

Jesus Perez

Tom Spencer

Michael Zandi

United Kingdom

Belinda Lennox Web: http://www.neuroscience.cam.ac.uk/directo...

Associated News Items


Publications

2015

Auyeung B, Lombardo MV, Heinrichs M, Chakrabarti B, Sule A, Deakin JB, Bethlehem RA, Dickens L, Mooney N, Sipple JA, Thiemann P, Baron-Cohen S (2015), “Oxytocin increases eye contact during a real-time, naturalistic social interaction in males with and without autism.” Transl Psychiatry 5:e507 Details

Khandakher G, Cousins L, Deakin JB, Lennox, Yolken R, Jones PB (2015), “Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment ” Lancet Psychiatry

2014

Deakin J, Lennox BR, Zandi MS (2014), “Antibodies to the N-methyl-d-aspartate receptor and other synaptic proteins in psychosis.” Biol Psychiatry 75(4):284-91 Details

Zandi MS, Deakin JB, Morris K, Buckley C, Jacobson L, Scoriels L, Cox AL, Coles AJ, Jones PB, Vincent A, Lennox BR (2014), “Immunotherapy for patients with acute psychosis and serum N-Methyl D-Aspartate receptor (NMDAR) antibodies: a description of a treated case series.” Schizophr Res 160(1-3):193-5 Details

2013

Deakin J, Lennox B (2013), “Psychotic symptoms in young people warrant urgent referral.” Practitioner 257(1759):25-8, 3 Details

2009

Deakin J, O'Loughlin C (2009), “STAR*D: a summary and UK perspective.” J Psychopharmacol 23(6):605-12 Details

2007

Chamberlain SR, Müller U, Deakin JB, Corlett PR, Dowson J, Cardinal RN, Aitken MR, Robbins TW, Sahakian BJ (2007), “Lack of deleterious effects of buspirone on cognition in healthy male volunteers.” J Psychopharmacol 21(2):210-5 Details

2005

Ersche KD, Fletcher PC, Lewis SJ, Clark L, Stocks-Gee G, London M, Deakin JB, Robbins TW, Sahakian BJ (2005), “Abnormal frontal activations related to decision-making in current and former amphetamine and opiate dependent individuals.” Psychopharmacology (Berl) 180(4):612-23 Details

2004

Deakin J, Aitken M, Robbins T, Sahakian BJ (2004), “Risk taking during decision-making in normal volunteers changes with age.” J Int Neuropsychol Soc 10(4):590-8 Details

Deakin JB, Aitken MR, Dowson JH, Robbins TW, Sahakian BJ (2004), “Diazepam produces disinhibitory cognitive effects in male volunteers.” Psychopharmacology (Berl) 173(1-2):88-97 Details

Deakin JB, Rahman S, Nestor PJ, Hodges JR, Sahakian BJ (2004), “Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial.” Psychopharmacology (Berl) 172(4):400-8 Details